June 15,
The reporter learned from the Guangdong Provincial Preventive Medicine Association that
600,000 recombinant subunits of COVID-19 vaccines arrived in Guangdong.
The vaccine is given a total of 3 doses throughout the course,
The target of vaccination is 18 years of age and older without contraindications to vaccination.
As of now,
China's landing of inactivated vaccines,
Recombinant subunit vaccine,
Three technical routes, including adenovirus vector vaccines
The covid-19 vaccine has arrived in Guangdong.
The technical principle is similar to the use of a very mature hepatitis B cho cell vaccine
Approved for emergency use! 600,000 recombinant subunits of COVID-19 vaccines arrived in Guangdong
The reporter learned that 600,000 recombinant subunits of new crown vaccines have arrived in Guangdong.
This recombinant novel coronavirus vaccine (cho cell) was jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui ZhifeiLong Kema Co., Ltd., a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd., and received special support from the National Key Research and Development Program, the Key Drug Research and Development Project of the Ministry of Science and Technology of the People's Republic of China, and the Chinese Academy of Sciences.
A few days ago, the vaccine was approved for emergency use.
So far
China has three technical routes
The new crown virus vaccine landed,
They are:
inactivated vaccines,
Adenovirus vector vaccine.
The recombinant novel coronavirus vaccine was made using a new technical route: genetic engineering technology was used to recombine the new coronavirus s protein receptor binding region (RBD) gene into the Chinese hamster ovary (cho) cell gene, express it in vitro to form rbd dimer, and add aluminum hydroxide adjuvant to improve immunogenicity. The principle of this technique is similar to that of the well-established hepatitis B cho cell vaccine.
Since the entire production process is a process of protein expression and purification, without the participation of live viruses, the production process is safe and easy to produce on a large scale. Judging from the use process and previous experimental results of recombinant protein vaccines in the past, the safety of recombinant protein vaccines can be guaranteed, and the adverse reaction rate is relatively low.
After 3 doses, the positive conversion rate of true virus neutralizing antibodies reached 97%
According to reports, the vaccination target of the recombinant new crown vaccine is 18 years old and above without contraindications to vaccination. The procedure is a total of 3 doses throughout the course. The interval between inoculations between adjacent 2 doses is recommended ≥ 4 weeks. The second dose should be completed within 8 weeks after the first dose and the third dose should be completed within 6 months after the first dose. Upper arm deltoid muscle injection.
With reference to the vaccine instructions, the contraindications to vaccination include:
1. those who are known to be allergic to any component of the vaccine, including excipients;
2. People suffering from acute diseases, serious chronic diseases, acute onset of chronic diseases and fever;
3. Pregnant women;
4. People with uncontrolled epilepsy and other progressive neurological disorders.
The recombinant subunit vaccine has good safety, the vast majority of subjects have no adverse reactions, and a very small number of subjects may have pain, redness or induration at the vaccination site, and can heal themselves within 1-3 days.
In terms of effectiveness, the phase II clinical trial of the three-dose recombinant protein subunit new coronavirus vaccine in adults aged 18-59 years showed that after receiving 2 doses of vaccine, the positive transversion of true virus neutralizing antibodies reached 83%, and after 3 doses, the positive transverseity of true virus neutralizing antibodies reached 97%, which was twice the serum neutralization antibody level of patients recovering from covid-19, and the positive transmissivity of rbd protein-binding antibodies reached 99%.
What is the difference between an inactivated COVID-19 vaccine and a recombinant subunit vaccine?
It is understood that the current new crown inactivated vaccine is the most familiar to everyone, belongs to the classic method, mature technology, easy to prepare. Antigenicity is similar to that of live viruses, does not replicate in the host, and is not contagious.
The recombinant subunit vaccine technology is advanced and mature, does not contain viral genes, has high safety, and can effectively induce b/t cell immunity.
Although the two vaccines have different technical routes, they are vaccines developed by combining the characteristics of the anti-pathogen and the pathogen itself, using a suitable process, which is safe and effective and the quality is controllable.
At present, all the new coronavirus vaccines used in China have been reviewed and approved by the drug regulatory department, and their safety and effectiveness are supported by certain data.
Hot Q&A
1. Why do recombinant sub-vaccines need to be given three doses?
Academician Gao Fu, director of the Chinese Center for Disease Control and Prevention, said in an interview that from the results of clinical trials, the effect of two injections has been very good, and the use of three injections is based on the fact that the new crown vaccine is a new vaccine, but according to the experience of other recombinant protein vaccines in the past, three injections will be better.
2. Can different types of COVID-19 vaccines be substituted for vaccination?
At this stage, experts recommend the use of the same vaccine product to complete vaccination, such as the first dose of recombinant subunit vaccine, the follow-up can only be vaccinated with this type of vaccine, can not be replaced by the new crown virus inactivated vaccine; or the first dose of inactivated vaccine, the follow-up injection can only be completed with inactivated vaccine, can not be replaced by recombinant subunit vaccine.
Text/Guangzhou Daily, Xinhuacheng reporter He Xuehua, correspondents Zeng Jiajun and He Yuhang
Source: Guangzhou Daily